stoxline Quote Chart Rank Option Currency Glossary
MEI Pharma, Inc. (MEIP)
2.89  0.04 (1.4%)    07-17 16:00
Open: 2.82
High: 2.8963
Volume: 7,278
Pre. Close: 2.85
Low: 2.82
Market Cap: 19(M)
Technical analysis
2024-07-17 5:28:49 PM
Short term     
Mid term     
Targets 6-month :  3.49 1-year :  4.07
Resists First :  2.99 Second :  3.49
Pivot price 2.84
Supports First :  2.86 Second :  2.77
MAs MA(5) :  2.85 MA(20) :  2.84
MA(100) :  3.31 MA(250) :  5.03
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  31.7 D(3) :  33.3
RSI RSI(14): 51.2
52-week High :  7.86 Low :  2.73
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ MEIP ] has closed below upper band by 25.5%. Bollinger Bands are 66.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.9 - 2.91 2.91 - 2.93
Low: 2.79 - 2.8 2.8 - 2.82
Close: 2.87 - 2.89 2.89 - 2.91
Company Description

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Headline News

Thu, 18 Jul 2024
MEI Pharma (NASDAQ:MEIP) Coverage Initiated by Analysts at - Defense World

Wed, 10 Jul 2024 Begins Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World

Tue, 28 May 2024
ZTS: 4 Pharma Stocks to Watch for Surprising Gains in June -

Mon, 13 May 2024
BAYRY: Top 4 Pharma Stocks to Consider This Month -

Wed, 20 Mar 2024
VTRS: 3 Pharma Stocks Outperforming the Competition -

Fri, 27 Oct 2023
MEIP - MEI Pharma, Inc. Latest Stock News & Market Updates - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 7 (M)
Shares Float 5 (M)
Held by Insiders 0.3 (%)
Held by Institutions 43.3 (%)
Shares Short 15 (K)
Shares Short P.Month 30 (K)
Stock Financials
EPS 3.92
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.65
Profit Margin 39.1 %
Operating Margin 30.5 %
Return on Assets (ttm) 12.3 %
Return on Equity (ttm) 61.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 10.02
EBITDA (p.s.) 3.11
Qtrly Earnings Growth 0 %
Operating Cash Flow -44 (M)
Levered Free Cash Flow 7 (M)
Stock Valuations
PE Ratio 0.73
PEG Ratio -7.9
Price to Book value 0.37
Price to Sales 0.28
Price to Cash Flow -0.44
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android